News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) FDA Approval Likely Today


7/26/2012 8:52:25 AM

According to Canaccord Genuity life sciences analyst Ritu Baral, AMRN FDA approval of cholesterol drug AMR101 is likely today. She told investors: “We expect three-year exclusivity will be granted to AMR101 under Hatch- Waxman’s ‘new clinical investigation’ clause. We think there is a good chance FDA may rule AMR101 is a new chemical entity, giving five-year exclusivity.” She added, “While the Hatch-Waxman statute (see main provisions of the bill) appears to present a black-and-white case against NCE status for AMR101, we note that FDA interpretation of the statute in the context of real- world clinical development, especially the development of naturally derived products that were approved with relatively poor characterization, leaves significant room for an alternate outcome.”

Read at Forbes
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES